Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Recently, the QuanNUA mass spectrometry system independently developed and manufactured by Intelligene Biosystems (Qingdao) Co., Ltd., the strategic partner of Bioperfectus Technologies, has successfully passed the inspection of Science and Technology Research Center of China Customs.

Sysmex said this week it had received manufacturing and marketing approval in Japan for a pair of assay kits to identify elevated amyloid beta concentrations characteristic of Alzheimer's disease.

The independently developed "COVID-19 antigen detection kit SARS-COV-2 Nucleocapsid (N) Antigen Rapid Detection Kit (Colloidal gold method)" by Synthgene Medical Technology was approved by the UK 5-year CTDA certification.

Following the broader life science tools space, proteomics firms experienced something of a retrenchment in 2022 as the boom times of the previous two years gave way to layoffs, strategic realignments, and delays.

China will scrap the quarantine requirement for international arrivals starting January 8, 2023, the country's National Health Commission said in a statement on Monday.

On December 26, Hangzhou Biotest Biotech announced that the COVID-19 antigen home self-test test kit produced by Advin, has passed laboratory verification and clinical research evaluation and has now obtained the EUA from the US Food and Drug Administration.

CTK Biotech said on Tuesday that its ImmuView COVID-19 Antigen Home Test has received Emergency Use Authorization from the US Food and Drug Administration.

In partnership with Minnesota Department of Health, Cue’s digital service offers an integrated solution to provide COVID-19 treatment options access across all populations

Recently, Chengdu Qi Tan Technology Co., Ltd. announced that it had completed the financing round C of 700 million CNY. This round of financing was led by Mei Tuan Capital, and the Capital Great Health Fund managed by HG Capital and BioTrack Capital continued to make additional investments.

Addition of next generation sequencing research panels, bioinformatics, positions IDT to become a leading oncology research solutions provider